Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy

N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy

US Patent 11413354 · Granted Aug 16, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Crystalline forms of an androgen receptor modulator2024
Multi-specific antibodies with affinity for human A33 antigen and DOTA metal com2024
Anti-CD20 antibody and uses thereof2023
Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pr2023
Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pr2023
Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pr2023
Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of pr2021
Multi-specific antibodies with affinity for human A33 antigen and DOTA metal com2021
Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of pr2021
Crystalline forms of an androgen receptor modulator2021
Systems and methods for determining optimum patient-specific antibody dose for t2020
Crystalline forms of an androgen receptor modulator2020